Halozyme Earnings Reports

Halozyme reported strong Q3 2024 results with a 34% increase in total revenue to $290 million and a 67% increase in net income to $137 million. The company raised its 2024 financial guidance, reflecting confidence in its growth trajectory, driven by ENHANZE pipeline advancements and new licensing agreements.

Halozyme reported a total revenue of $231 million, net income of $93 million, adjusted EBITDA of $137 million, GAAP diluted EPS of $0.72, and non-GAAP diluted EPS of $0.91 for Q2 2024. Royalty revenue increased 12% year-over-year to $125 million. The company maintains its recently increased 2024 financial guidance.

Halozyme reported a strong first quarter in 2024, with a 21% increase in revenue to $196 million. Net income reached $77 million, and non-GAAP diluted EPS was $0.79. The company is reiterating its full-year financial guidance, supported by the continued advancement of ENHANZE partner products and pipeline.

Halozyme's Q4 2023 revenue increased by 27% year-over-year to $230 million, driven by royalty revenue growth, higher product sales, and an increase in milestone revenue. GAAP diluted EPS was $0.65, and non-GAAP diluted EPS was $0.82. The company is reiterating its 2024 financial guidance and announced a new $750 million share repurchase program.

Halozyme reported a 3% increase in revenue to $216.0 million, driven by growth in ENHANZE® revenue streams. Royalty revenue increased 15% year-over-year to $114.4 million. GAAP diluted EPS was $0.61, and non-GAAP diluted EPS was $0.75. The company raised its EBITDA and non-GAAP EPS guidance for the full year 2023.

Halozyme reported a strong second quarter with revenue increasing 45% YOY to $221.0 million and non-GAAP EPS of $0.74. The company raised its 2023 non-GAAP diluted EPS guidance to $2.65-$2.75 and updated revenue guidance to $825-$845 million.

Halozyme reported a 38% year-over-year increase in revenue to $162.1 million for Q1 2023, driven by royalty revenue and product sales from the Antares Pharma acquisition. GAAP diluted earnings per share was $0.29, and non-GAAP diluted earnings per share was $0.47. The company reiterates its 2023 revenue guidance of $815-$845 million and EBITDA of $415-$440 million.

Halozyme reported a 78% increase in revenue for the fourth quarter of 2022, reaching $181 million, driven by increased royalty revenue and the acquisition of Antares Pharma. Full year revenue increased by 49% to $660.1 million. The company is projecting continued growth in 2023 with revenue guidance of $815 million to $845 million.

Halozyme reported an 80% year-over-year increase in revenue for the third quarter of 2022, reaching $209 million. This growth was driven by increased royalty revenue, the addition of product sales from the Antares Pharma acquisition, and increased revenues from collaborative agreements. The company reiterated its 2022 revenue guidance of $655 million to $685 million, representing 48%-55% growth over 2021.

Halozyme Therapeutics reported a strong second quarter with a 12% increase in revenue, driven by royalty revenue and the acquisition of Antares Pharma. The company is raising its full-year revenue guidance to $655 million to $685 million.

Halozyme reported a strong first quarter in 2022, with a 32% year-over-year increase in revenue, driven by record royalty revenues. The company also announced the pending acquisition of Antares Pharma, expected to boost long-term growth.

Halozyme Therapeutics reported a decrease in revenue for the fourth quarter, primarily driven by a decrease in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue. Despite the revenue decrease, the company saw a strong performance across its business, highlighted by record full year revenue from royalties.

Halozyme reported strong second-quarter results with a significant increase in revenue and earnings per share. The company raised its full-year revenue guidance to $425-$445 million and GAAP EPS guidance to $1.55-$1.70. Key drivers include milestone revenues from collaborations, increased royalty revenue, and growth in product sales.

Halozyme reported a strong start to 2021, with revenue increasing to $89.0 million, driven by milestone revenues and increased royalty revenue from subcutaneous DARZALEX®. The company completed a convertible senior notes sale and repurchased a significant portion of existing notes, strengthening its balance sheet.

Halozyme reported a successful fourth quarter, driven by the launch of DARZALEX® SC with ENHANZE®. The company transitioned to a profitable, high-growth company with strong prospects for continued growth.

Halozyme Therapeutics, Inc. reported third quarter 2020 financial results with revenue of $65.3 million and EPS of $0.25. The company is raising its full year 2020 financial guidance due to improved outlook for royalties and greater visibility on anticipated milestone revenues.

Halozyme reported a profitable second quarter with earnings per share of $0.19. The company saw revenue growth driven by collaboration payments and FDA approvals for partnered drugs. They are maintaining their financial outlook for the full year 2020.

Halozyme Therapeutics, Inc. reported a decrease in revenue for the first quarter of 2020, primarily due to a $30 million upfront payment from argenx in the prior year period. The company experienced a net loss of $6.1 million, or $0.04 per share, compared to a net income of $1.8 million, or $0.01 per share, in the first quarter of 2019. Despite these challenges, Halozyme reaffirmed its 2020 financial guidance, expecting revenues between $230 million and $245 million and earnings per share between $0.60 and $0.75.

Halozyme's fourth-quarter revenue was $53.7 million, compared to $60.2 million for the fourth quarter of 2018. The net loss for the fourth quarter was $34.4 million, or $0.24 per share, compared to a net loss in the fourth quarter of 2018 of $2.1 million, or $0.01 per share. The company completed $200 million worth of share repurchases under the Board of Directors authorized capital return program.